Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 136Head and Neck Neoplasms 96Squamous Cell Carcinoma of Head and Neck 89Carcinoma, Non-Small-Cell Lung 58Colonic Neoplasms 44Rectal Neoplasms 38Neoplasm Metastasis 34Neoplasms 28Pancreatic Neoplasms 24Lung Neoplasms 18Carcinoma, Squamous Cell 18Stomach Neoplasms 15Tongue Neoplasms 13Esophageal Neoplasms 13Salivary Gland Neoplasms 11Recurrence 10Breast Neoplasms 10Laryngeal Neoplasms 9Mouth Neoplasms 8Esophageal Squamous Cell Carcinoma 8Carcinoma 8Adenocarcinoma Of Esophagus 8Adenocarcinoma of Lung 7Neoplasms, Squamous Cell 6Hypopharyngeal Neoplasms 6Carcinoma, Renal Cell 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Oropharyngeal Neoplasms 5Nasopharyngeal Carcinoma 5Carcinoma, Hepatocellular 5

Interventions

sapanisertib 2tovorafenib 1serabelisib 1pevonedistat 1Paclitaxel 1MLN 8237 1Irinotecan 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Nonhematologic Malignancies × Cetuximab × Clear all
NCT02327169 2020-02-25

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Takeda

Phase 1 Completed
81 enrolled 33 charts

Advanced Nonhematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡